Tag: Reversible MAO-A inhibitor

  • Toloxatone

    Reversible MAO-A inhibitor

    A 5-(hydroxymethyl)oxazolidinone RIMA approved in France in 1984; an early-generation reversible inhibitor of MAO-A.

    Abstract

    Toloxatone (5-(hydroxymethyl)-3-(3-methylphenyl)oxazolidin-2-one; CAS 29218-27-7; molecular formula C11H13NO3; molecular weight 207.23) is an oxazolidinone RIMA developed at Delalande in France and approved there in 1984 under the trade name Humoryl. The compound is a reversible competitive MAO-A inhibitor with a clinical profile broadly comparable to moclobemide; selectivity for MAO-A over MAO-B is approximately 50-fold at therapeutic concentrations. Plasma half-life is approximately 2 hours; hepatic metabolism is the primary clearance pathway. Tyramine restriction is not required at clinical doses. Clinical efficacy in major depressive disorder was demonstrated in French trials but the drug never received approval outside France and clinical use has substantially declined. Used historically and as a reference oxazolidinone RIMA in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.